Trial Profile
A randomized phase III study of denosumab before curettage for giant cell tumor of bone (JCOG1610, Preoperative Denosumab for GCTB RPIII)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone cancer; Giant cell tumours
- Focus Therapeutic Use
- 18 Sep 2022 Status changed from active, no longer recruiting to discontinued, as per Results published in the Japanese Journal of Clinical Oncology
- 18 Sep 2022 Results published in the Japanese Journal of Clinical Oncology
- 05 Jan 2021 Status changed from recruiting to active, no longer recruiting.